These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 23910807)

  • 1. Anaphylactic reaction to polyethylene-glycol conjugated-asparaginase: premedication and desensitization may not be sufficient.
    Sahiner UM; Yavuz ST; Gökce M; Buyuktiryaki B; Altan I; Aytac S; Tuncer M; Tuncer A; Sackesen C
    Pediatr Int; 2013 Aug; 55(4):531-3. PubMed ID: 23910807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anaphylactic reaction to polyethylene glycol-conjugated asparaginase: premedication and desensitization may not be sufficient.
    Walenciak J; Mlynarski W; Zalewska-Szewczyk B
    Pediatr Int; 2014 Feb; 56(1):130-1. PubMed ID: 24548205
    [No Abstract]   [Full Text] [Related]  

  • 3. An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia.
    Ettinger LJ; Kurtzberg J; Voûte PA; Jürgens H; Halpern SL
    Cancer; 1995 Mar; 75(5):1176-81. PubMed ID: 7850718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia.
    Soyer OU; Aytac S; Tuncer A; Cetin M; Yetgin S; Sekerel BE
    J Allergy Clin Immunol; 2009 Apr; 123(4):895-9. PubMed ID: 19081614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L-asparaginase activity and anti-L-asparaginase antibody as biomarkers in estimating PEG-asp-related anaphylaxis risk in childhood acute lymphoblastic leukemia patients.
    Cui J; Jiang L; Xu B; Bai Y
    Allergol Immunopathol (Madr); 2023; 51(3):28-35. PubMed ID: 37169557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol.
    Henriksen LT; Harila-Saari A; Ruud E; Abrahamsson J; Pruunsild K; Vaitkeviciene G; Jónsson ÓG; Schmiegelow K; Heyman M; Schrøder H; Albertsen BK;
    Pediatr Blood Cancer; 2015 Mar; 62(3):427-33. PubMed ID: 25418987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time Course and Management of Protracted Anaphylaxis Due to PEG-Asparaginase.
    Fertal SA; Bradeen HA; Friesen E; Heath JL
    J Pediatr Hematol Oncol; 2021 Apr; 43(3):e385-e387. PubMed ID: 32815880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hypersensitivity reactions associated with the use of asparaginase in children with acute lymphoblastic leukemia].
    Ovalle B P; Azócar M M; Nicklas D C; Villarroel C M; Morales V J
    Andes Pediatr; 2021 Apr; 92(2):182-192. PubMed ID: 34106156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia].
    Cooperation Group of Phase II Clinical Trial of PEG-Asp
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):29-33. PubMed ID: 18512312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring of anti-L-asparaginase antibody and L-asparaginase activity levels in a pediatric patient with acute lymphoblastic leukemia and hypersensitivity to native Escherichia coli L-asparaginase during desensitization courses.
    Kawahara Y; Morimoto A; Hayase T; Kashii Y; Fukuda T; Momoi MY
    J Pediatr Hematol Oncol; 2014 Mar; 36(2):e91-3. PubMed ID: 23689289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Advances on the role of pegaspargase in the treatment of childhood leukemia].
    Liu L; Xie XT
    Zhongguo Dang Dai Er Ke Za Zhi; 2014 Feb; 16(2):155-60. PubMed ID: 24568909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
    Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
    Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Activity of Erwinia-asparaginase after anaphylactic reaction to Peg-asparaginase].
    Viña Romero MM; García Gil S; Nazco Casariego GJ; Merino Alonso J; Gutiérrez Nicolás F
    An Pediatr (Engl Ed); 2019 Mar; 90(3):187-188. PubMed ID: 29705180
    [No Abstract]   [Full Text] [Related]  

  • 14. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study.
    Abshire TC; Pollock BH; Billett AL; Bradley P; Buchanan GR
    Blood; 2000 Sep; 96(5):1709-15. PubMed ID: 10961868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful use of octreotide as a chemoprotectant for prevention of PEG-asparaginase-induced pancreatitis.
    Buie LW; Moore J; van Deventer H
    Pharmacotherapy; 2014 Aug; 34(8):e149-51. PubMed ID: 25112526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comprehensive strategy to address shortage of Erwinia asparaginase in pediatric acute lymphoblastic leukemia.
    Vagrecha A; Tao V; Corless R; Colon C; Redner A; Atlas M
    Expert Rev Clin Pharmacol; 2023; 16(8):763-769. PubMed ID: 37294084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).
    Kurtzberg J; Asselin B; Bernstein M; Buchanan GR; Pollock BH; Camitta BM
    J Pediatr Hematol Oncol; 2011 Dec; 33(8):610-6. PubMed ID: 22042277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peg-asparaginase for acute lymphoblastic leukemia.
    Rytting M
    Expert Opin Biol Ther; 2010 May; 10(5):833-9. PubMed ID: 20345338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma.
    August KJ; Farooki S; Fulbright JM; August A; Portnoy JM; Pommert L; Burke MJ; Guest EM
    Pediatr Blood Cancer; 2020 Jan; 67(1):e28021. PubMed ID: 31571395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
    Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
    Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.